Announced Date: 2024-11-14 (November 14, 2024)
Asset Name: LM-299
Licensor: LaNova Medicines Ltd. (LaNova) (China)
Licensee (Buyer): MSD (tradename of Merck & Co., Inc., USA)
.
Asset Modality: BsAbs (Bispecific antibody)
Asset Target: PD-1 and VEGF (Programmed cell death protein-1, Vascular endothelial growth factor)
Current Stage: China phase 1 ;
Scope of Authority:
LaNova has granted MSD an exclusive global license to develop, manufacture and commercialize LM-299.
.
Deal Detail:
Upfront payment of $588 million,
Milestone payments up to $2.7 billion,
Total $3.288 billion plus.
.
Link:
